Home Blogs Contributing Editors Feature

The Quest To Reinfuse Venture Capital Into Biotech Funding

Written by
Longtime biotech industry observer Stelios Papadopoulos, Ph.D., remembers exactly where he was when Genentech had its initial public offering (IPO) in 1980 — defending his…

Accelerating The Drug Approval Process

Written by
When David Pyott took the reins of Allergan (NYSE: AGN) as president and CEO in 1998, the stock was trading at just under $8 a…

By A Web Design